TD Cowen lowered the firm's price target on Endava to $6.50 from $8 and keeps a Hold rating on the shares. The firm said they posted 2Q26 results largely aligned with plan and raised FY26 CC guide by about 1pt. 3Q26 outlook versus the Street weighed by FX/investments, but implied 4Q26 topped consensus by roughly 2%.
